Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Phase 1/2 Active not recruiting 702 enrolled AstraZeneca

Non-randomizedSequentialOpen-labelTreatment

Summary

This research is designed to determine if experimental treatment with PARP inhibitor, AZD5305, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced solid tumors.

Timeline

Start: 2020-11-12
Primary completion: 2027-05-28
Completion: 2027-05-28

Publications

Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, Johannes J, Leonard E, Macdonald R, Maglennon G, Nikkila J, O'Connor MJ, Smith A, Southgate H, Wilson J, Yates J, Cosulich S, Leo E. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper. Clin Cancer Res. 2022 Nov 1;28(21):4724-4736. doi: 10.1158/1078-0432.CCR-22-0301.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Camizestrant	Other / unclassified	—	Oral
Subject	Carboplatin	Small molecule	—	Intravenous
Subject	Datopotamab deruxtecan	Monoclonal antibody	—	Intravenous
Subject	Paclitaxel	Small molecule	—	Intravenous
Subject	Saruparib	Small molecule	—	Oral
Subject	Trastuzumab deruxtecan	Monoclonal antibody	—	Intravenous

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies

Summary

Timeline

Publications

Drugs

Indications